References
1. Rastogi P, Anderson SJ, Bear HD, et
al. Preoperative chemotherapy: updates of national surgical adjuvant
breast and bowel project protocols B-18 and B-27. Journal of
Clinical Oncology. 2008;26(5):778-785.
2. Volders J, Haloua M, Krekel N, et
al. Neoadjuvant chemotherapy in breast-conserving surgery–Consequences
on margin status and excision volumes: a nationwide pathology study.European Journal of Surgical Oncology (EJSO). 2016;42(7):986-993.
3. Moran MS, Schnitt SJ, Giuliano AE,
et al. Society of Surgical Oncology–American Society for Radiation
Oncology consensus guideline on margins for breast-conserving surgery
with whole-breast irradiation in stages I and II invasive breast cancer.International Journal of Radiation Oncology* Biology* Physics.2014;88(3):553-564.
4. Fragomeni SM, Sciallis A, Jeruss
JS. Molecular Subtypes and Local-Regional Control of Breast Cancer.Surgical oncology clinics of North America. 2018;27(1):95-120.
5. Myers DJ, Walls AL. Atypical Breast
Hyperplasia. In: StatPearls. Treasure Island (FL): StatPearls
Publishing
Copyright © 2021, StatPearls Publishing LLC.; 2021.
6. Worsham MJ, Abrams J, Raju U, et
al. Breast cancer incidence in a cohort of women with benign breast
disease from a multiethnic, primary health care population. The
breast journal. 2007;13(2):115-121.
7. Hartmann LC, Degnim AC, Santen RJ,
Dupont WD, Ghosh K. Atypical hyperplasia of the breast—risk assessment
and management options. New England Journal of Medicine.2015;372(1):78-89.
8. Fowble B, Hanlon A, Patchefsky A,
et al. The presence of proliferative breast disease with atypia does not
significantly influence outcome in early-stage invasive breast cancer
treated with conservative surgery and radiation. International
Journal of Radiation Oncology* Biology* Physics. 1998;42(1):105-115.
9. Goldstein NS, Lacerna M, Vicini F.
Cancerization of lobules and atypical ductal hyperplasia adjacent to
ductal carcinoma in situ of the breast: significance for
breast-conserving therapy. American journal of clinical
pathology. 1998;110(3):357-367.
10. Arora S, Menes TS, Moung C, Nagi
C, Bleiweiss I, Jaffer S. Atypical ductal hyperplasia at margin of
breast biopsy—is re-excision indicated? Annals of surgical
oncology. 2008;15(3):843-847.
11. Lennington WJ, Jensen RA, Dalton
LW, Page DL. Ductal carcinoma in situ of the breast. Heterogeneity of
individual lesions. Cancer. 1994;73(1):118-124.
12. Li S, Liu J, Yang Y, et al.
Impact of atypical hyperplasia at margins of breast-conserving surgery
on the recurrence of breast cancer. Journal of cancer research and
clinical oncology. 2014;140(4):599-605.
13. Hammond MEH, Hayes DF, Dowsett M,
et al. American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for immunohistochemical testing
of estrogen and progesterone receptors in breast cancer (unabridged
version). Archives of pathology & laboratory medicine.2010;134(7):e48-e72.
14. Chen K, Zeng Y, Jia H, et al.
Clinical outcomes of breast-conserving surgery in patients using a
modified method for cavity margin assessment. Annals of surgical
oncology. 2012;19(11):3386-3394.
15. Page DL, Rogers LW. Combined
histologic and cytologic criteria for the diagnosis of mammary atypical
ductal hyperplasia. Human pathology. 1992;23(10):1095-1097.
16. Coopey SB, Mazzola E, Buckley JM,
et al. The role of chemoprevention in modifying the risk of breast
cancer in women with atypical breast lesions. Breast Cancer Res
Treat. 2012;136(3):627-633.
17. Tozbikian G, Brogi E, Vallejo CE,
et al. Atypical ductal hyperplasia bordering on ductal carcinoma in
situ: interobserver variability and outcomes in 105 cases.International journal of surgical pathology. 2017;25(2):100-107.
18. Simpson JF. Update on atypical
epithelial hyperplasia and ductal carcinoma in situ. Pathology.2009;41(1):36-39.
19. Holland R, Veling SH, Mravunac M,
Hendriks JH. Histologic multifocality of tis, T1–2 breast carcinomas
implications for clinical trials of breast‐conserving surgery.Cancer. 1985;56(5):979-990.
20. Recht A, Silen W, Schnitt SJ, et
al. Time-course of local recurrence following conservative surgery and
radiotherapy for early stage breast cancer. International Journal
of Radiation Oncology* Biology* Physics. 1988;15(2):255-261.
21. Kurtz JM, Amalric R, Brandone H,
et al. Local recurrence after breast‐conserving surgery and
radiotherapy. Frequency, time course, and prognosis. Cancer.1989;63(10):1912-1917.
22. DiPaola RS, Orel SG, Fowble BL.
Ipsilateral breast tumor recurrence following conservative surgery and
radiation therapy. Oncology (Williston Park, NY).1994;8(12):59-68; discussion 71, 75.
23. Swisher SK, Vila J, Tucker SL, et
al. Locoregional control according to breast cancer subtype and response
to neoadjuvant chemotherapy in breast cancer patients undergoing
breast-conserving therapy. Annals of surgical oncology.2016;23(3):749-756.
24. Hartmann LC, Radisky DC, Frost
MH, et al. Understanding the premalignant potential of atypical
hyperplasia through its natural history: a longitudinal cohort study.Cancer Prevention Research. 2014;7(2):211-217.
25. Menes TS, Kerlikowske K, Lange J,
Jaffer S, Rosenberg R, Miglioretti DL. Subsequent breast cancer risk
following diagnosis of atypical ductal hyperplasia on needle biopsy.JAMA oncology. 2017;3(1):36-41.
26. Fisher B, Costantino JP,
Wickerham DL, et al. Tamoxifen for the prevention of breast cancer:
current status of the National Surgical Adjuvant Breast and Bowel
Project P-1 study. Journal of the National Cancer Institute.2005;97(22):1652-1662.
27. Page DL, Dupont WD, Rogers LW,
Rados MS. Atypical hyperplastic lesions of the female breast. A
long‐term follow‐up study. cancer. 1985;55(11):2698-2708.
28. Dowsett M, Dunbier AK. Emerging
biomarkers and new understanding of traditional markers in personalized
therapy for breast cancer. Clinical Cancer Research.2008;14(24):8019-8026.
29. Cortazar P, Zhang L, Untch M, et
al. Pathological complete response and long-term clinical benefit in
breast cancer: the CTNeoBC pooled analysis. The Lancet.2014;384(9938):164-172.
30. Cho DH, Bae SY, You JY, et al.
Lymph node ratio as an alternative to pN staging for predicting
prognosis after neoadjuvant chemotherapy in breast cancer. The
Kaohsiung journal of medical sciences. 2018;34(6):341-347.
31. van Nijnatten TJ, Simons J,
Moossdorff M, et al. Prognosis of residual axillary disease after
neoadjuvant chemotherapy in clinically node-positive breast cancer
patients: isolated tumor cells and micrometastases carry a better
prognosis than macrometastases. Breast cancer research and
treatment. 2017;163(1):159-166.
32. Choi J, Laws A, Hu J, Barry W,
Golshan M, King T. Margins in Breast-Conserving Surgery After
Neoadjuvant Therapy. Ann Surg Oncol. 2018;25(12):3541-3547.